Health
Nivolumab Plus Paclitaxel Shows Clinical Activity in Advanced Gastric Cancer Subgroup – Cancer Network
Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr…
Second-line treatment with nivolumab (Opdivo) plus paclitaxel showed clinical activity and a manageable safety profile in patients with Epstein-Barr virusrelated, microsatellite instabilityhigh (MSI-H)/mismatch repair deficient (dMMR) or PD-L1positive advanced gastric cancer, according to findings from a phase 1/2 study (NCT02951091) presented during Week 1 of the virtual AACR Annual Meeting 2021.1
At a median follow-up of 10.8 months, data from the phase 2 cohort (n = 48) showed that the combination…
-
Noosa News19 hours agoToombul Shopping Centre site thrown lifeline after Mirvac announces sale with ‘priority’ to build new retail centre
-
General20 hours agoAllegations against ex-Attorney-General Mark Dreyfus removed from Linda Reynolds action against Commonwealth
-
General8 hours agoDriver charged after fatal alleged hit-run crash at Hillier
-
Noosa News22 hours agoMirvac to sell site to Irvine Group